4536
SANTEN PHARMACEUTICAL CO.,LTD.
参天製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
266,257
Mar 2023
279,037
Mar 2024
301,965
Mar 2025
300,004
Mar 2026
291,624
Operating profit(million JPY)
Mar 2022
35,886
Mar 2023
-3,090
Mar 2024
38,541
Mar 2025
46,880
Mar 2026
47,797
Operating profit margin(%)
Mar 2022
13.48
Mar 2023
-1.11
Mar 2024
12.76
Mar 2025
15.63
Mar 2026
16.39
Profit before tax(million JPY)
Mar 2022
35,616
Mar 2023
-5,799
Mar 2024
29,874
Mar 2025
47,481
Mar 2026
47,442
Profit(million JPY)
Mar 2022
27,218
Mar 2023
-14,948
Mar 2024
26,642
Mar 2025
36,256
Mar 2026
37,369
Total assets(million JPY)
Mar 2022
459,976
Mar 2023
421,179
Mar 2024
435,699
Mar 2025
409,277
Mar 2026
423,033
Cash and cash equivalents(million JPY)
Mar 2022
83,014
Mar 2023
57,903
Mar 2024
94,582
Mar 2025
92,997
Mar 2026
80,875
Cash flows from operating activities(million JPY)
Mar 2022
46,043
Mar 2023
37,147
Mar 2024
72,649
Mar 2025
60,928
Mar 2026
43,500
Cash flows from investing activities(million JPY)
Mar 2022
-35,169
Mar 2023
-26,777
Mar 2024
-6,145
Mar 2025
-8,223
Mar 2026
-12,974
Cash flows from financing activities(million JPY)
Mar 2022
5,557
Mar 2023
-37,220
Mar 2024
-34,031
Mar 2025
-53,307
Mar 2026
-49,348
Return on equity(%)
Mar 2022
8.4
Mar 2023
-4.7
Mar 2024
8.9
Mar 2025
12.2
Mar 2026
12.8
Equity ratio(%)
Mar 2022
73.4
Mar 2023
69.8
Mar 2024
70.2
Mar 2025
69.9
Mar 2026
70.2
Earnings per share(JPY per share)
Mar 2022
68.07
Mar 2023
-38.6
Mar 2024
72.59
Mar 2025
103.98
Mar 2026
114.04
Net assets per share(JPY per share)
Mar 2022
843.6
Mar 2023
783.3
Mar 2024
843.24
Mar 2025
839.2
Mar 2026
923.75
Dividend per share(JPY per share)
Mar 2022
32
Mar 2023
32
Mar 2024
33
Mar 2025
36
Mar 2026
38
Payout ratio(%)
Mar 2022
47.01
Mar 2023
-
Mar 2024
45.46
Mar 2025
34.62
Mar 2026
33.32
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.